Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Unternehmen & Branche
| Name | Annexon, Inc. |
|---|---|
| Ticker | ANNX |
| CIK | 0001528115 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 719,4 Mio. USD |
| Beta | 1,15 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -206,690,000 | -1.34 | 277,571,000 | 211,648,000 | |
| 2025-09-30 | 10-Q | -54,922,000 | -0.37 | 229,142,000 | 161,442,000 | |
| 2025-06-30 | 10-Q | -49,156,000 | -0.34 | 264,573,000 | 199,017,000 | |
| 2025-03-31 | 10-Q | -54,356,000 | -0.37 | 303,027,000 | 243,788,000 | |
| 2024-12-31 | 10-K | -138,200,000 | -1.01 | 350,071,000 | 293,105,000 | |
| 2024-09-30 | 10-Q | -34,824,000 | -0.25 | 378,776,000 | 331,560,000 | |
| 2024-06-30 | 10-Q | -29,610,000 | -0.23 | 406,085,000 | 361,079,000 | |
| 2024-03-31 | 10-Q | -25,176,000 | -0.21 | 304,069,000 | 262,405,000 | |
| 2023-12-31 | 10-K | -134,237,000 | -1.77 | 297,674,000 | 250,556,000 | |
| 2023-09-30 | 10-Q | -32,482,000 | -0.43 | 203,816,000 | 156,839,000 | |
| 2023-06-30 | 10-Q | -35,188,000 | -0.47 | 233,013,000 | 184,724,000 | |
| 2023-03-31 | 10-Q | -38,676,000 | -0.52 | 268,778,000 | 214,861,000 | |
| 2022-12-31 | 10-K | -141,947,000 | -2.60 | 285,096,000 | 231,194,000 | |
| 2022-09-30 | 10-Q | -35,054,000 | -0.51 | 312,722,000 | 260,602,000 | |
| 2022-06-30 | 10-Q | -37,137,000 | -0.96 | 220,704,000 | 168,044,000 | |
| 2022-03-31 | 10-Q | -35,373,000 | -0.92 | 250,569,000 | 200,614,000 | |
| 2021-12-31 | 10-K | -130,323,000 | -3.40 | 287,040,000 | 231,909,000 | |
| 2021-09-30 | 10-Q | -35,598,000 | -0.93 | 310,156,000 | 264,477,000 | |
| 2021-06-30 | 10-Q | -31,294,000 | -0.82 | 331,784,000 | 295,335,000 | |
| 2021-03-31 | 10-Q | -26,060,000 | 333,117,000 | 321,422,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Carson William H. | Director | Open Market Purchase | 8,000 | 6.20 | 49,600.00 | +13,9% | |
| 2026-03-10 | Carson William H. | Director | Open Market Purchase | 8,000 | 5.67 | 45,360.00 | +12,7% | |
| 2026-03-02 | Lew Jennifer | Officer, EVP & CHIEF FINANCIAL OFFICER | Open Market Sale | -5,565 | 5.42 | -30,162.30 | -8,4% | |
| 2026-03-02 | ARTIS DEAN RICHARD | Officer, EVP & CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,894 | 5.43 | -32,004.42 | -8,9% | |
| 2026-03-02 | Yednock Ted | Officer, EVP & CHIEF INNOVATION OFFICER | Open Market Sale | -5,566 | 5.42 | -30,167.72 | -8,4% | |
| 2026-03-02 | Dananberg Jamie | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,820 | 5.43 | -31,602.60 | -8,8% | |
| 2026-03-02 | Overdorf Michael | Officer, EVP & CHIEF BUSINESS OFFICER | Open Market Sale | -4,339 | 5.42 | -23,517.38 | -6,6% | |
| 2026-02-18 | Yednock Ted | Officer, EVP & CHIEF INNOVATION OFFICER | Open Market Sale | -7,857 | 5.11 | -40,149.27 | -11,2% | |
| 2026-02-18 | Dananberg Jamie | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,290 | 5.10 | -26,979.00 | -7,5% | |
| 2026-02-18 | Lew Jennifer | Officer, EVP & CHIEF FINANCIAL OFFICER | Open Market Sale | -7,851 | 5.11 | -40,118.61 | -11,2% | |
| 2026-02-18 | Overdorf Michael | Officer, EVP & CHIEF BUSINESS OFFICER | Open Market Sale | -6,225 | 5.10 | -31,747.50 | -8,9% | |
| 2026-02-18 | ARTIS DEAN RICHARD | Officer, EVP & CHIEF SCIENTIFIC OFFICER | Open Market Sale | -5,290 | 5.10 | -26,979.00 | -7,5% | |
| 2025-12-30 | Carson William H. | Director | Open Market Purchase | 4,115 | 5.02 | 20,657.30 | +5,8% | |
| 2025-12-01 | Choi Jung | Director | Open Market Purchase | 33,000 | 4.19 | 138,270.00 | +38,7% | |
| 2025-12-01 | Carson William H. | Director | Open Market Purchase | 4,115 | 4.47 | 18,394.05 | +5,1% | |
| 2025-11-21 | Satter Muneer A | Director | Open Market Purchase | 422,613 | 4.28 | 1,808,783.64 | +505,8% | |
| 2025-11-20 | Satter Muneer A | Director | Open Market Purchase | 400,000 | 4.48 | 1,792,000.00 | +501,1% | |
| 2025-11-19 | Satter Muneer A | Director | Open Market Purchase | 500,000 | 3.94 | 1,970,000.00 | +550,8% | |
| 2025-11-18 | Satter Muneer A | Director | Open Market Purchase | 500,000 | 3.18 | 1,590,000.00 | +444,6% | |
| 2025-11-17 | Satter Muneer A | Director | Open Market Purchase | 500,000 | 2.99 | 1,495,000.00 | +418,0% | |
| 2025-10-30 | Carson William H. | Director | Open Market Purchase | 4,115 | 3.17 | 13,044.55 | +3,6% | |
| 2025-09-30 | Carson William H. | Director | Open Market Purchase | 4,115 | 3.05 | 12,550.75 | +3,5% | |
| 2025-09-02 | Carson William H. | Director | Open Market Purchase | 4,115 | 2.09 | 8,600.35 | +2,4% | |
| 2025-07-30 | Carson William H. | Director | Open Market Purchase | 4,115 | 2.43 | 9,999.45 | +2,8% | |
| 2025-07-14 | Lew Jennifer | Officer, EVP & CHIEF FINANCIAL OFFICER | Open Market Sale | -1,117 | 2.58 | -2,881.86 | -0,8% | |
| 2025-06-30 | Carson William H. | Director | Open Market Purchase | 4,115 | 2.46 | 10,122.90 | +2,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.